Pharmaceutical Industry Articles & Reports - Page 2

Review essential features of Anatomic Pathology LIMS, including digital pathology integration, compliance, and workflows for histopathology and cytology.

Examine how Isomorphic Labs uses AlphaFold AI to advance its first computationally designed oncology and immunology therapeutics into clinical trials.

Explore the updated EU GMP Annex 1 guidelines for sterile manufacturing. Learn how to implement a risk-based Contamination Control Strategy (CCS) for compliance

Understand how AI automates regulatory medical writing for CTD Module 2 summaries in IND and NDA submissions, including efficiency gains and compliance risks.

Analyze the AI-enabled precision proteomics market through the Alamar Biosciences $191M IPO, NULISA technology, and the future of protein biomarker detection.

Learn about CDISC SEND datasets for FDA nonclinical submissions. This guide explains SDTM framework alignment, SENDIG rules, and regulatory compliance timelines

Explore Kailera Therapeutics' $625M IPO and GLP-1 obesity pipeline. This analysis covers clinical data, dual agonists, and the 2026 biotech market reopening.

This report examines pharma data lakehouse architecture for R&D. Review how Databricks, Snowflake, and Apache Iceberg manage life sciences and clinical data.

Examine AI clinical study report automation. This guide explains the technical process of converting SDTM and ADaM datasets into Module 5 submission documents.

An in-depth comparison of AI biology foundation models like AlphaFold 3, ESM3, Boltz-2, and Chai-1. Analyze their architectures, benchmarks, and use cases.

Examine the FDA Commissioner's National Priority Voucher (CNPV) pilot program. This guide explains the new 1-2 month accelerated drug review pathway and rules.

Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.

Analyze the FDA NAM roadmap for animal-free drug approval. Learn how advanced in silico models, AI tools, and organ-on-chip systems replace animal testing.

Track 2026 Big Pharma and hyperscaler AI deals. This report analyzes enterprise cloud partnerships, infrastructure investments, and GxP compliance trends.

Analyze the $1B Merck and Google Cloud partnership. This report explains how agentic AI and Gemini Enterprise apply to pharmaceutical R&D and data workflows.

Analyze the $838M Merck-Infinimmune AI antibody discovery deal. Understand how the Anthrobody screening platform and GLIMPSE language model engineer biologics.

An overview of the $1B NVIDIA-Eli Lilly AI lab, detailing its 5-year compute strategy, DGX SuperPOD infrastructure, and foundation models for drug discovery.

Examine ChatGPT Enterprise admin controls, security settings, and compliance features. This report details SSO, RBAC, data residency, and workspace policies.

Examine how UVA's YuelDesign uses 3D AI diffusion models in drug discovery. Learn how co-designing ligands with flexible protein pockets improves binding.

Analyze the application of generative AI in antibiotic discovery. This report examines the Phare Bio-Basilea partnership and Gram-negative drug development.

Analyze OpenAI's GPT-Rosalind, a biochemical reasoning model for life sciences. Learn how Amgen, Moderna, and Thermo Fisher apply this AI to drug discovery.

Analyze the Chai Discovery and Eli Lilly partnership in AI biologics design. Examine how generative models like Chai-2 impact antibody drug development.

Examine the $50M GSK-Noetik agreement licensing AI foundation models for oncology. Learn how spatial biology and virtual cells advance R&D and drug discovery.

Analyze the Boltz-Pfizer AI drug discovery partnership. This report examines the application of open-source biomolecular foundation models in pharma R&D.